Moderna, Inc. (ETR:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 49.63B +453.2% |
| Revenue (ttm) | 1.95B -27.6% |
| Net Income | -2.76B |
| EPS | -7.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,019 |
| Open | 114.90 |
| Previous Close | 121.80 |
| Day's Range | 112.30 - 136.54 |
| 52-Week Range | 19.37 - 142.38 |
| Beta | 0.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.
Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.
Moderna Soars 129% for the Week | Closing Bell
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Sally Bakewell, Carol Massar and Emily Graffeo. -------- More...
Moderna Stock (MRNA) Jumps 13% Despite JPMorgan’s Sell Rating
Shares in Moderna ($MRNA) climbed by 13% to $151 per share on Friday afternoon. This came even after JPMorgan’s five-star analyst Jessica Fye repeated her Sell rating on the U.S.
Moderna, Robinhood, Ross Stores, and More Stocks That Explain Today's Market
Moderna shares rise to close out a week of wild swings, while crypto stocks extend their recent rally.
Moderna's personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Doctors and patients are excited about the possible breakthrough, but some analysts believe there's too much hype.
Moderna Is Up 350% Since Our Recommendation. Here's What to Do Next.
Moderna's breakthrough highlights a broader transformation, as AI accelerates the clinical development of therapies at a pace that would have seemed unimaginable a few years ago.
Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough
$51.5 billion. That's Moderna's market valuation as of Thursday, marking a more than $18 billion decline from Wednesday's closing valuation of $69.6 billion.
How Moderna's Historic Short Squeeze Upended the AI Chip Trade
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Why Moderna Stock Is Plunging Today — and What Wall Street Sees Ahead
Moderna (NASDAQ:MRNA) stock is giving back part of Wednesday’s huge gain, falling about 18% on Thursday as Wall Street’s response to the latest cancer-vaccine results gives investors reason to cash…
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.
Moderna stock falls 20% after record rally as valuation concerns emerge
Moderna shares fell sharply in trading on Thursday as investors took profits after the biotechnology company posted its biggest one-day gain following positive Phase 3 cancer vaccine results. The retr...
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target
Moderna ($MRNA) stock rallied 177% on Wednesday after a cancer vaccine from the biotech company and Merck ($MRK) showed positive initial results in its first-ever late-stage trial. Reacting to the fav...
Moderna, Coinbase, Strategy, Walmart, Alibaba, and More Stocks That Explain Today's Market
Moderna tumbles as investors take some profit following Wednesday's surge, while crypto stocks rally.
Why Moderna Stock Is Falling Today after a 177% Surge and What Wall Street Expects Next – August 20
Moderna ($MRNA) stock fell more than 10% in pre-market trading on Thursday after shares jumped nearly 177% on Wednesday. Investors appear to be taking profits after the stock’s biggest one-day…
Why Moderna Stock's Historic Surge Is a Big Lesson for Markets
Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.
Moderna price target raised to $150 from $50 at UBS
UBS analyst Michael Yee raised the firm’s price target on Moderna to $150 from $50 and keeps a Neutral rating on the shares. Moderna (MRNA) and Merck surged 176% and…
Moderna Stock Drops, But Still Above Wall Street Targets — Should You Buy Now?
Moderna ($MRNA) stock is down by over 14% in premarket trading on Thursday. The drop came after shares surged over 175% in the previous session following the success of its…
Opinion | Moderna's Road to a Cancer Vaccine
The company says a trial met its goal to prevent melanoma recurrence.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.